Award Number: W81XWH-08-2-0026

TITLE: Personalized Medicine in Veterans with Traumatic Brain Injuries

PRINCIPAL INVESTIGATOR: Giulio Maria Pasinetti, M.D., Ph.D.

CONTRACTING ORGANIZATION: Bronx Veterans Medical Research Foundation Inc.
Bronx, NY 10468

REPORT DATE: May 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
The study was designed to identify clinically accessible molecular biomarkers of traumatic brain injury (TBI) prior to definitive clinical diagnosis using high throughput microRNA technology. Specifically, these studies were meant to identify, characterize, and validate microRNA biomarker species whose content in peripheral blood mononuclear cells (PBMC) could help to distinguish TBI cases from the Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) veteran population. During the past years, we conducted a Biomarker Discovery study using a high-throughput Array chip platform and identified 18 candidate TBI small RNA biomarkers. Using independent Q-PCR assays, we confirmed that 13 of these candidate small RNA biomarker species are, indeed, significantly down-regulated in PBMC of TBI compared to non-TBI control veteran cases. Additionally, we used unsupervised clustering analysis and demonstrated that the differential regulation of these small RNA biomarkers in clinically accessible blood cells is capable of distinguishing between TBI and non-TBI OEF/OIF veteran cases. Lastly, we identified a 3-biomarker panel capable of distinguishing TBI from non-TBI control veteran cases with 89% accuracy, 82% selectivity, and 78% specificity. The majority of TBI cases in our biomarker study were co-morbid with PTSD, and our non-TBI control cases were selected to match for PTSD diagnosis. Thus, our identified panel of 13 small RNA biomarkers likely represents biological indices selective for TBI. During the past year, we recruited 13 new cases (6 TBI and 7 non-TBI cases). Together with the cases recruited in previous years, we currently have a total of 83 cases, comprised of 17 TBI and 66 non-TBI control cases, which are available for Biomarker Validation studies. Power calculation confirmed that our presently available 17 TBI and 66 control cases sufficiently provide a power of 0.95 (alpha level = 0.05) for detecting differences in the contents of small RNA TBI biomarkers in PBMC specimens from TBI compared to non-TBI cases. Real-time quantitative PCR (Q-PCR) analysis of the 83-case Biomarker Validation study cohort is ongoing. Outcomes will validate the value of TBI biomarkers from clinically accessible PBMC, either individually or in combination(s), to correctly diagnose TBI and non-TBI in OEF/OIF veterans.

15. SUBJECT TERMS
Operation Iraqi Freedom (OIF); Operation Enduring Freedom (OEF); Traumatic Brain Injury (TBI)
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>7</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>7</td>
</tr>
<tr>
<td>Conclusion</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>8</td>
</tr>
<tr>
<td>Appendices</td>
<td>8</td>
</tr>
</tbody>
</table>
Introduction
Traumatic brain injury (TBI) is a major casualty identified among veterans deployed to Afghanistan and the Persian Gulf region in support of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF). TBI is caused by one or more concussive insults to the head or a penetrating head injury that disrupts the normal function of the brain, leading to either transient or chronic impairments in physical, cognitive, emotional and behavioral functions. TBI in OEF/OIF veterans is largely the result of concussive injuries from blast-producing weaponry. Overall, veterans have lower attention scores, although it is not yet known if mild TBI might contribute to this observation. Nevertheless, veterans from prior conflicts exposed to blasts have shown evidence of mild TBI and attention difficulties when compared to similar veterans without blast exposure. Early diagnosis of chronic TBI is important for preventing further progression of symptoms that can disrupt a veteran’s life upon return from service. Mild TBI can be difficult to diagnose and, when coupled with psychological illness, can be either misdiagnosed or missed altogether. Traditionally, physicians and scientists have viewed and interpreted diseases at the ‘visual’ clinical level. With the advent of genomics and proteomics technologies, personalized medicine offers the promise and potential of uncovering the largely ‘unseen’ details of disease causality, onset, and progression. As have been proposed, these studies were designed to be conducted in collaboration with The War-related Illness and Injury Study Center (WRIISC), Department of Veteran Affairs, New Jersey Health Care System (DVANJHCS), East Orange, NJ, and were designed to identify genomic-microRNA fingerprints from clinically accessible blood cell components as independent biological indexes that will allow us to identify unique molecular indices of Persistent Postconcussive Syndrome as well as well as other significant injury-related factors associated with mild TBI in OEF/OIF veterans.

Body
The study was designed to identify clinically accessible molecular biomarkers of TBI prior to definitive clinical diagnosis using high throughput microRNA technology. Specifically, these studies were meant to identify, characterize, and validate microRNA biomarker species whose content in peripheral blood mononuclear cells (PBMC) could help to distinguish TBI injury cases within a veteran population following deployment in support of OEF or OIF. The overall study is separated into a Biomarker Discovery study to identify candidate microRNA biomarkers, and a Biomarker Validation study to validate the sensitivity and specificity of microRNA biomarkers, either individually or as panels of multiple biomarkers, to correctly identify TBI and control cases in an independent cohort of TBI and non-TBI veterans.

The WRIISC at East Orange, New Jersey received final Department of Defense (DoD) IRB approval to commence recruitment on July 29, 2009. As we have stated in our Year 4 Annual Progress Report, we initiated volunteer recruitment on October 31, 2009. Our inclusion criteria for recruitment were male and female 18-75 years with or without a history of TBI, who have completed a clinical evaluation at the East Orange, New Jersey WRIISC. Participants were classified as having a history of mTBI if they positively endorsed at least one of 4 items on the Veteran traumatic brain injury screening tool (VAT-BIST) (Donnelly et al., 2011) and had a score at least one standard deviation below the norm for age and education on the Repeatable Battery for Neuropsychological Testing (RBANS) (Randolph, 1998). Classification criteria for control cases are DVBIC confirmation of no injury to the head and a RBANS score of less than
one standard deviation below the norm. Cases with inter-current infections of inflammatory-related conditions were excluded.

Starting on October 31, 2009, when recruitment was initiated, and continuing through the time when we submitted our Year 4 Annual Report on 30th May, 2012, we recruited and collected PBMC specimens from 110 cases, including 29 TBI and 81 non TBI cases (Table I). No problems were encountered with the volunteer recruitment or blood collection and processing. The proportion of veterans classified as mild TBI in our recruited cohort is consistent with, and even slightly above, previous prevalence estimates of 12% (Schneiderman et al., 2008) reported in a cross-sectional survey of 2,235 active duty guard and reserve OEF/OIF veterans.

<table>
<thead>
<tr>
<th></th>
<th>mTBI</th>
<th>Non-TBI Control</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recruitment: Years 1 - 4</td>
<td>29</td>
<td>81</td>
<td>110</td>
</tr>
<tr>
<td>Cases used for Biomarker Discovery studies</td>
<td>11</td>
<td>16</td>
<td>27</td>
</tr>
<tr>
<td>Cases available for Biomarker Validation studies at the end of Year 4</td>
<td>18</td>
<td>65</td>
<td>83</td>
</tr>
</tbody>
</table>

Table I: The number of mTBI and non-TBI control veterans recruited during Years 1, 2, 3 and 4. A total of 110 OEF/OIF veteran cases were recruited in Years 1-4, among which 29 (26.4%) were mTBI cases. Also shown are the numbers of cases used for Biomarker Discovery studies as well as the number of cases available for Biomarker Validation studies.

We have tested 11 TBI and 16 non-TBI cases for an Interim Biomarker Discovery study. As RNA preparations from some of the cases did not meet quality control criteria, our final Biomarker Discovery studies were conducted using 9 TBI and 9 non TBI cases. At the time when we submitted our Year 4 Annual Report, we had 18 TBI and 66 non-TBI (a total of 83) cases that were not used in our Biomarker Discovery studies and therefore were available for Biomarker Validation studies (Table I).

Details of our interim microRNA Biomarker Discovery study were provided in our Year 4 Annual Progress Report. Key outcomes from our Biomarker Discovery studies are as follows: Using a high throughputs array chip platform, we initially identified 18 candidate small RNA TBI biomarkers from our Veteran study cohort. Using independent Q-PCR assays, we confirmed that 13 of the 18 candidate small RNA biomarkers are, indeed, differentially regulated in the PBMC of TBI compared to non-TBI veteran cases. The 13 confirmed small RNA biomarkers include 12 small nucleolar RNA (ACA48, ENSG199411, HBII-239, HBII-289, U15B, U27, U35A, U55, U56, U58B, U83A, U91) and 1 miRNA (Has-miR-671-5p). Each of the 13 confirmed small RNA biomarkers are found in significantly lower levels in PBMC specimens from TBI compared to non-TBI control veteran cases. Using unsupervised clustering, we found that the differential regulation of these small RNA biomarkers in clinically accessible blood cells is capable of distinguishing TBI from non-TBI OEF/OIF Veteran cases. Moreover, we identified a 3-biomarker panel capable of distinguishing TBI from non-TBI veteran cases with 89% accuracy, 82% selectivity and 78% specificity. Outcomes from our Biomarker Discovery studies have been published in the American Journal of Neurodegenerative Disease (Pasinetti et al., 012; Appendix 1). In our manuscript, we noted that the majority of TBI cases in our study cohort are
co-morbid with PTSD based on a PTSD diagnosis criterion of having a score of 50 or more in the PTSD Checklist – Civilian Version (Harris et al., 2008), and that our non-TBI control cases were selected to match for PTSD diagnosis. Thus, our identified panel of 13 small RNA biomarkers likely represents biological indices selective for TBI. Moreover, we noted that TBI cases in our biomarker discovery studies were recruited after an average interval of 3.9 years following their last deployment (deployment-to-recruitment interval ranging from 0.7 to 10.2 years, with a median interval of 3.4 years). Thus, changes in the regulation of these small RNA TBI biomarkers that we observed are not acute TBI responses, but likely represent long-term pathophysiological consequences subsequent to TBI. Lastly, we observed that genes relevant to neural circuits, synapses and neural plasticity processes are also expressed in circulating blood cells, such as PBMC. Significant down-regulation of select small RNA biomarkers was observed in PBMC specimens from our Veteran TBI population long after their deployment that might reflect long-term molecular alterations in the central nervous system contributing to the onset and progression of clinical TBI phenotypes. We attached a copy of our TBI biomarker manuscript as an appendix (Appendix I) accompanying our Year 4 Annual Progress Report. Based on outcomes from our Biomarker Discovery studies identifying and confirming 13 small RNA biomarkers from our Biomarker Discovery cohort, we are continuing with our Biomarker Validation studies to test the value of these biomarkers in terms of correctly diagnosing TBI and non-TBI cases in a new independent cohort of Veterans as was proposed.

Our collaborators at The War Related Illness and Injury Study Center in the East Orange New Jersey Health Care System (WRIISC/NJHCS) have finalized patient recruitments for our proposed Biomarker Discovery and Biomarker Validation studies. We currently have 83 unused cases (18 TBI and 65 non TBI cases) available for Biomarker validation studies. Power analysis showed that our currently available 18 TBI cases and 66 control cases will provide a power of 0.95 (alpha level = 0.05) for detecting differences in the contents of small RNA TBI biomarkers in PBMC specimens from TBI compared to non-TBI cases. The WRIISC/NJHCS has sent samples from all currently available 83 veteran cases by commercial currier to Dr. Pasinetti’s group at the JJ Peters VA Medical Center for Biomarker Validation studies. Q-PCR analysis of the 83 case Biomarker Validation study cohort is ongoing. Moreover, we have applied for and granted a one year no-cost extension to complete our proposed Biomarker Validation studies.
**Key Research Accomplishments**

1. We conducted Biomarker Discovery studies using a high-throughput Array chip platform and identified 18 candidate TBI small RNA biomarkers.
2. Using independent Q-PCR assays, we confirmed that 13 of these candidate small RNA biomarker species are, indeed, significantly down-regulated in PBMC of TBI compared to non-TBI control veteran cases.
3. Using unsupervised clustering, we found that the differential regulation of these small RNA biomarkers in clinically accessible blood cells is capable of differentiating between TBI and non-TBI OEF/OIF veteran cases.
4. We identified a 3-biomarker panel capable of distinguishing TBI from non-TBI control veteran cases with 89% accuracy, 82% selectivity, and 78% specificity.
5. The majority of TBI cases in our biomarker study were co-morbid with PTSD and our non-TBI control cases were selected to match for PTSD diagnosis. Thus, our identified panel of 13 small RNA biomarkers likely represents biological indices selective for TBI.
6. We have recruited OEF/OIF Veteran volunteers. We now have a total of 18 TBI and 65 non-TBI control cases for our proposed Biomarker Validation studies. We calculated that the number of currently available cases will provide a power of 0.95 (alpha level = 0.05) for detecting differences in the contents of small RNA TBI biomarkers in PBMC specimens from TBI compared to non-TBI cases.
7. We have published one manuscript on the identification and characterization of small RNA TBI biomarkers from clinically accessible PBMC.

**Reportable Outcomes**

N/A

**Conclusion**

Our Biomarker Discovery studies to date have identified a panel of small RNA TBI biomarkers whose contents in clinically accessible blood cells provide a criterion for the correct diagnosis of TBI from non-TBI veteran cases with high accuracy, specificity, and selectivity. The majority of TBI cases in our biomarker study were co-morbid with PTSD and our non-TBI control cases were selected to match for PTSD diagnosis. Thus, our identified panel of 13 small RNA biomarkers likely represents biological indices selective for TBI. We have recruited a total of 110 cases, comprised of 29 mTBI and 81 non-TBI cases. Some of the cases were used in our Biomarker Studies, with a remaining 83 cases (18 mTBI and 65 non-TBI cases) available for Biomarker Validation studies. We calculated that the currently available 83 cases are sufficiently powered for our proposed Biomarker Validation studies. In ongoing studies, we are analyzing the PBMC specimens from the Biomarker Validation study cohort using Q-PCR to validate individual or combination of small RNA TBI biomarkers as surrogate biological indices of TBI. Outcomes from our combined Biomarker Discovery and Validation studies will lead to improved TBI detection in OEF/OIF veterans, more sensitive outcome measurements for future clinical trials, a better understanding of the biological mechanisms underlying concussive TBI, and insights into novel therapeutic targets for OEF/OIF veterans with TBI.
References


Appendices
Introduction

Traumatic brain injury (TBI) is a condition often identified among Veterans deployed to the Persian Gulf region in support of Operation Enduring Freedom (OEF) or Operation Iraqi Freedom (OIF). TBI is caused by one or more concussive insults to the head or a penetrating head injury that disrupts the normal functions of the brain, leading to either transient or chronic impairments in physical, cognitive, emotional and behavioral functions [1-6]. In OEF/OIF Veterans, TBI is largely the result of concussive injuries from blast-producing weaponry [7]. Veterans exposed to blasts from prior conflicts have shown evidence of mild TBI (mTBI) and attention difficulties when compared to similar Veterans without blast exposure. Mild TBI can be difficult to diagnose and, when coupled with psychological illness, can be either misdiagnosed or missed altogether. Traditionally, physicians and scientists have viewed and interpreted diseases at the ‘visual’ clinical level. However, with the advent of genomics and proteomics technologies, personalized medicine offers the promise and potential of uncovering the largely ‘unseen’ details of disease causality, onset, and progression.

New evidence has highlighted defects in neural
Biological surrogates for distinguishing TBI from PTSD

circuits and synapses, and the plastic processes controlling these functions, in TBI [8-13]. While gene products relevant to these processes are expressed in the brain, some of these genes are also expressed in circulating blood cells, such as peripheral blood mononuclear cells (PBMCs) [14-17]. Consistent with this, recent studies have illustrated that PBMC-associated biomarkers may provide insights into the pathogenesis of neurological disorders such as Alzheimer’s disease and may be used to monitor disease diagnosis and progression [18,19]. Thus, PBMCs may also provide an ideal clinically accessible “window” into the brain, reflecting molecular alterations following TBI which might contribute to the onset and progression of clinical TBI phenotypes.

Small non-coding RNAs, including microRNA (miRNA) and small nucleolar RNA (snoRNA), are increasingly recognized for their roles in the regulation of cellular processes in health and disease [20]. Select small non-coding RNAs, particularly miRNA, have been implicated in neurological disorders [21-23]. It is possible that miRNA and other small non-coding RNAs might contribute to the onset and/or progression of clinical complications following TBI [24]. Exploring the feasibility of identifying clinically accessible TBI biomarkers, we identified select small non-coding RNA fingerprints from clinically accessible PBMCs that may be used as independent biological indexes of mTBI in OEF/OIF Veterans. Outcomes from our studies suggest that additional applications of the clinically accessible small non-coding RNA biomarkers to current diagnostic criteria may lead to improved mTBI detection and more sensitive outcome measures for clinical trials.

Materials and methods

18 OIF and OEF Veterans (9 mTBI and 9 non-mTBI control cases) were recruited by The War Related Illness and Injury Study Center (WRIISC), Department of Veterans Affairs, New Jersey Health Care System (DVANJHCS), East Orange, NJ. Male and female participants were included if they were between 18-75 years of age and completed a clinic evaluation at the New Jersey WRIISC. Participants were included regardless of their mTBI history. Outcomes from our studies suggest that additional applications of the clinically accessible small non-coding RNA biomarkers to current diagnostic criteria may lead to improved mTBI detection and more sensitive outcome measures for clinical trials.

PBMC isolation

Blood specimens were collected by venipuncture and drawn into BD Vacutainer CPT Cell Preparation Tubes. PBMCs were isolated from freshly collected blood specimens following manufacturer’s instructions (Becton, Dickinson and Company) and were stored at -80°C until use.

RNA preparation and high throughput analysis of small non-coding RNAs

Total RNA was isolated from approximately 10-50 mg of PBMCs using RNA STAT-60 according to the manufacturer’s instructions (Tel-Test,
Biological surrogates for distinguishing TBI from PTSD

Friendswood, TX, USA). Immediately prior to RNA labeling, the purity and concentration of RNA samples were determined from OD_{260/280} readings using a dual beam UV spectrophotometer and RNA integrity was determined by capillary electrophoresis using the RNA 6000 Nano Lab-on-a-Chip kit and the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) as per the manufacturer’s instructions.

Total RNA was directly modified and labeled using the FlashTag™ HSR Biotin RNA Labeling Kit according to the manufacturer’s instructions (Genisphere, Hatfield, PA). Verification of biotin labeling was obtained by an enzyme-linked oligoabsorbant assay (ELOSA) using Immobilizer™ Amino – 8 well strips (Nunc/Thermo Fisher Scientific, Rochester, NY, USA) according to instructions supplied by Genisphere. Labeled cRNA

Table 1. Demographic characteristics of mTBI and non-mTBI control cases we used in our interim Biomarker Discovery study. Mild TBI classification is based on positive endorsement of the VA traumatic brain injury screen (VAT-BIS) and a score of at least one standard deviation below the norm for age and education on the Repeatable Battery for Neuropsychological Testing (RBANS). Non-mTBI case classification is based on negative endorsement of VAT-BIS and a RBANS score of less than one standard deviation below the norm. PTSD diagnosis is based on a score of 50 or more on the PTSD Checklist – Civilian Version. Average age: mTBI group, 31.6±7.0 yrs; non-mTBI group, 29.8±8.2 yrs. Interval between their last deployment and recruitment into this study: mTBI group, 3.9±2.7 yrs; non-mTBI group 2.6±2.1 yrs. Average duration of education: mTBI group, 13.3±1.3; non-mTBI group, 13.0±2.4 yrs. Percentage of males: mTBI group, 78%; non-mTBI group, 67%. Percent of cases with co-morbid PTSD: mTBI group, 89%; non-mTBI group, 78%.

<table>
<thead>
<tr>
<th>Case</th>
<th>mTBI/Ctl</th>
<th>Age</th>
<th>Gender</th>
<th>Ethnicity</th>
<th>Interval (yrs) since last deployment</th>
<th>Education (yrs)</th>
<th>Comorbidity PTSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>31529</td>
<td>mTBI</td>
<td>38</td>
<td>Male</td>
<td>Black, non-Hispanic</td>
<td>3.0</td>
<td>14</td>
<td>Yes</td>
</tr>
<tr>
<td>33297</td>
<td>mTBI</td>
<td>41</td>
<td>Male</td>
<td>Native American</td>
<td>4.3</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>33825</td>
<td>mTBI</td>
<td>31</td>
<td>Male</td>
<td>Black, non-Hispanic</td>
<td>3.4</td>
<td>16</td>
<td>Yes</td>
</tr>
<tr>
<td>33828</td>
<td>mTBI</td>
<td>42</td>
<td>Male</td>
<td>Black, non-Hispanic</td>
<td>0.7</td>
<td>14</td>
<td>Yes</td>
</tr>
<tr>
<td>33888</td>
<td>mTBI</td>
<td>27</td>
<td>Female</td>
<td>White Hispanic</td>
<td>4.5</td>
<td>14</td>
<td>Yes</td>
</tr>
<tr>
<td>33931</td>
<td>mTBI</td>
<td>23</td>
<td>Male</td>
<td>White Hispanic</td>
<td>1.2</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>33947</td>
<td>mTBI</td>
<td>25</td>
<td>Male</td>
<td>Black, non-Hispanic</td>
<td>2.8</td>
<td>13</td>
<td>No</td>
</tr>
<tr>
<td>33881</td>
<td>mTBI</td>
<td>32</td>
<td>Female</td>
<td>White Hispanic</td>
<td>10.2</td>
<td>13</td>
<td>Yes</td>
</tr>
<tr>
<td>33811</td>
<td>mTBI</td>
<td>27</td>
<td>Male</td>
<td>Black, non-Hispanic</td>
<td>4.8</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>31705</td>
<td>Non TBI Ctrl</td>
<td>27</td>
<td>Male</td>
<td>Black, non-Hispanic</td>
<td>3.4</td>
<td>12</td>
<td>No</td>
</tr>
<tr>
<td>33565</td>
<td>Non TBI Ctrl</td>
<td>25</td>
<td>Male</td>
<td>White Hispanic</td>
<td>1.1</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>33578</td>
<td>Non TBI Ctrl</td>
<td>30</td>
<td>Female</td>
<td>White Hispanic</td>
<td>4.3</td>
<td>16</td>
<td>Yes</td>
</tr>
<tr>
<td>33596</td>
<td>Non TBI Ctrl</td>
<td>35</td>
<td>Male</td>
<td>White Hispanic</td>
<td>3.8</td>
<td>16</td>
<td>Yes</td>
</tr>
<tr>
<td>33598</td>
<td>Non TBI Ctrl</td>
<td>49</td>
<td>Male</td>
<td>White Hispanic</td>
<td>0.7</td>
<td>9</td>
<td>Yes</td>
</tr>
<tr>
<td>33821</td>
<td>Non TBI Ctrl</td>
<td>26</td>
<td>Female</td>
<td>White Hispanic</td>
<td>0.2</td>
<td>16</td>
<td>No</td>
</tr>
<tr>
<td>33834</td>
<td>Non TBI Ctrl</td>
<td>24</td>
<td>Male</td>
<td>White Hispanic</td>
<td>2.8</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>33913</td>
<td>Non TBI Ctrl</td>
<td>22</td>
<td>Female</td>
<td>Black, non-Hispanic</td>
<td>6.5</td>
<td>12</td>
<td>Yes</td>
</tr>
<tr>
<td>33930</td>
<td>Non TBI Ctrl</td>
<td>30</td>
<td>Male</td>
<td>Black, non-Hispanic</td>
<td>1.0</td>
<td>12</td>
<td>Yes</td>
</tr>
</tbody>
</table>
(1.0 μg) was hybridized for 16 hr at 48°C to Affymetrix microRNA v1.0 arrays (Affymetrix, Santa Clara, CA, USA), which contain probe sets for 1,500 small non-coding RNAs, including microRNA (miRNA), small nucleolar RNA (snoRNA), small Cajal body-specific RNA (scaRNA), and 5.8S ribosomal RNA (rRNA). Array content was derived from the Sanger miRBase miRNA database v11 (April 15, 2008; http://microrna.sanger.ac.uk), snoRNABase (www.snorna.biotoul.fr) and the Ensembl Archive (www.ensembl.org). Arrays were washed and stained on a Fluidics Station 450 (Affymetrix) according to the manufacturer’s recommended procedures. The arrays were stained with phycoerythrin-conjugated streptavidin (Invitrogen/Life Technologies, Carlsbad, CA, USA) and the fluorescence intensities determined using a GCS 3000 7G high-resolution confocal laser scanner and AGCC software (Affymetrix). The scanned images were analyzed with the miRNA QC tool (Affymetrix) using RNA global background correction, quantile normalization and median polish summarization to generate quantified data (as recommended by Genisphere). Quality control metrics for arrays included normalized signal values > 1000 for five spike-in control oligo probe sets (Genisphere).

Small RNA probe sets exhibiting significant differential expression (SDE) were identified using the following steps in GeneMaths XT (Applied Maths, Austin TX): 1) Probed sets with array detection p-values ≤ 0.05 for all samples in at least one experimental group were selected for further analysis, 2) Performed Discriminant Analysis (DA) and determined the largest percentage of remaining probe sets that permitted correct group assignment of samples in unsupervised hierarchical clustering by the Unweighted Pair-Group Method using Arithmetic averages (UPGMA) based on cosine correlation of row mean centered log2 signal values; this was the top 50%-tile, 3) In the DA top 50%-tile, selected probe sets with absolute signal log2 fold changes ≥ 1.0 and independent t-test p-values ≤ 0.05 adjusted for multiple testing error by the Benjamini-Hochberg false-discovery rate (FDR) correction method [28]. Unsupervised hierarchical clustering of probes sets and heat map generation were performed in GeneMaths XT following row mean centering of log2 transformed MAS5.0 signal values; probe set clustering was performed by the UPGMA method using Cosine correlation as the similarity metric. For comparative purposes, clustered heat maps included probe sets for spike-in controls (Genisphere), or endogenous small RNAs exhibiting: 1) Array detection p-values ≤ 0.05, and 2) either a) a log2 signal value standard deviation ≤ 0.025 for all samples or b) in the DA top 50%-tile with an FC > 1.3 in the opposite direction of the selected SDE profile.

**Confirmatory quantitative Real-Time Polymerase Chain Reaction (qPCR) studies**

We identified specific target sequences for each of the 18 candidate small RNA biomarkers (Table 2). Based on the sequence information, qPCR primer sets specific for each of the biomarkers were custom-designed and synthesized commercially by Applied Biosystems (Carlsbad, CA). One microgram of total RNA was used to prepare complementary DNA (cDNA) libraries using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, California) in a total volume of 20 μL. Data were normalized relative to those for the 58S ribosomal RNA. Levels of targeted small non-coding RNA were expressed relative to those in control groups using the 2ΔΔCt method [29].

**Results**

Using the Affymetrix Human gene 1.0 ST Array chip as a high-throughput platform, we analyzed the expression profile of 1500 small non-coding RNAs in our human PBMC specimens from the mTBI and non-mTBI cases in our OEF/OIF Veteran study cohort. We detected a total of 428 small RNA species from our PBMC specimens: 190 miRNAs, 220 snoRNAs, 8 small cytoplasmic RNAs and 10 ribosomal RNAs. In an initial exploratory data analysis, we conducted a principal component analysis of all signals detected to segregate mTBI and non-mTBI cases. The analysis revealed that data sets from all cases can be clustered into an mTBI or non-mTBI group, with the exception of mTBI case #33811, which is plotted far from the mTBI and non-mTBI clusters (Figure 1). Results from the principal component analysis suggested that the dataset generated from case #33811 was an outlier. Based on this and the fact that the quality of RNA extracted from this case was poor (not shown), we excluded case #33811 from subsequent statistical analyses.
Biological surrogates for distinguishing TBI from PTSD

Using high throughput small non-coding RNA datasets, we continued to search for candidate mTBI biomarkers and the corresponding targeted nuclear acid sequence used for the construction of selective probe systems for qPCR studies. Two criteria were used to identify candidate small RNA biomarkers for mTBI: 1) group changes (mTBI vs. non-mTBI groups) must be associated with a magnitude of $\geq 1.5$-fold, and 2) group changes must be statistically significant with $p < 0.05$, based on t-test analysis followed by the application false discovery rate corrections for multi-sampling errors. We identified 18 candidate small RNA biomarkers meeting both criteria: 4 miRNAs, 13 snoRNAs and 1 small scaRNA. Interestingly, we observed that all candidate small RNA biomarkers are significantly down-regulated in mTBI versus non-mTBI cases.

Independent qPCR validation of candidate small non-coding RNA biomarkers

We next used an independent quantitative real-
Biological surrogates for distinguishing TBI from PTSD

...time polymerase chain reaction (qPCR) procedure to assess the expression of individual candidate small RNA biomarkers in PBMC specimens from the same 9 mTBI and 9 non-mTBI cases used in our high-throughput biomarker discovery studies. Primer sets specific for each of the biomarkers were custom-designed and synthesized commercially by Applied Biosystems (Carlsbad, CA). Using these primer sets, we conducted qPCR studies and assessed the contents of individual candidate small RNA biomarkers in PBMCs of mTBI compared to non-mTBI cases. Results from our qPCR studies confirmed that 13 of the 18 candidate small RNA biomarkers are, indeed, differentially regulated in PBMCs of mTBI compared to non-mTBI veteran cases (Figure 3). The 13 confirmed small RNA biomarkers include 12 small nucleolar RNA (ACA48, ENSG199411, HBII-239, HBII-289, U15B, U27, U35A, U55, U56, U58B, U83A, U91) and 1 miRNA (Has-miR-671-5p) (Figure 3). Consistent with evidence from our RNA array platform, each of the 13 confirmed small RNA biomarkers are found in significantly lower levels in PBMC specimens from mTBI compared to non-mTBI veteran cases (Figure 3).

Exploring the potential value of novel small RNA biomarkers for segregating mTBI from non-mTBI veteran cases

Based on results from our qPCR biomarker confirmation studies, we next assessed the value of the 13 confirmed small RNA biomarkers as a criterion to correctly diagnose mTBI versus non-mTBI veteran cases. Using an unsupervised clustering analysis, we found the 13 confirmed mTBI biomarkers effectively segregated the cases correctly into mTBI and non-mTBI groups, with the exception of 2 of the non-mTBI cases which were incorrectly identified as mTBI (Figure 4A). We continued unsupervised clustering analyses to test the efficacy of individual or a combination of qPCR confirmed biomarkers to correctly segregate mTBI and non-mTBI veteran cases. Outcomes from these analyses led to the identification of a 3 small nucleolar biomarker panel, comprised of HBII-289, ENSG199411 and U35A, which is capable of distinguishing mTBI from non-mTBI veteran cases with 89% accuracy, 82% selectivity and 78% specificity (Figure 4B).

Discussion

Evidence has suggested that appropriate interventions can reduce functional impairment after mTBI [30,31,32,33]. In order to demonstrate the efficacy of clinical interventions, research must identify the biological, clinical, and neurological indices that are sensitive to the detection of functional impairments after mTBI. Results from our studies led to the identification of 13 novel clinically accessible small RNA mTBI...
Biological surrogates for distinguishing TBI from PTSD

Biomarkers, including 12 small snoRNA and 1 miRNA. Using qPCR, we have independently confirmed that each of these biomarkers is significantly down-regulated in PBMC specimens from mTBI compared to non-mTBI veteran cases. Among the 13 mTBI biomarkers, we demonstrated that a panel of 3 snoRNA - HBII-289, ENSG199411 and U35A - is capable of distinguishing mTBI from non-mTBI veterans with 89% accuracy, 82% selectivity and 78% specificity. Collectively, our evidence suggests that additional applications of the small RNA biomarkers we have identified, particularly the three biomarker panel, to current diagnostic criteria may improve mTBI detection and provide more sensitive outcome measures for clinical trials.

PTSD is commonly co-morbid with mTBI in OEF/OIF Veterans [34,35]. We note that the majority of Veterans with mTBI in our biomarker study have co-morbid PTSD and that our non-mTBI
Biological surrogates for distinguishing TBI from PTSD

Thus, our identified 13 small RNA biomarkers likely represent biological indices selective for mTBI. Moreover, mTBI cases in our biomarker discovery studies were recruited after an average interval of 3.9 years following their last deployment (deployment-to-recruitment interval: ranging from 0.7 to 10.2 years, with a median interval of 3.4 years) (Table 1). Thus, changes in the regulation of these small RNA mTBI biomarkers that we observed are not acute mTBI responses, but likely represent long-term physiological consequences subsequent to mTBI experienced during deployment.

The pathological implication of our observation that select small nucleolar RNA and miRNA are differentially regulated in the PBMCs of mTBI relative to non-mTBI veteran cases is currently unknown. Small nucleolar RNA and miRNA are members of a family of non-coding RNAs that are involved in many physiological cellular processes and are also known to contribute to molecular alterations in pathological conditions [36]. SnoRNAs are short RNA sequences comprised of ~60-220 nucleotides. They are primarily known for their role as guide molecules for site-specific methylation and pseudouridylation of other RNAs, particularly rRNA, as well as tRNA and small nuclear RNAs. These chemical alterations are required for proper RNA processing and ribosome function as well as for proper function of the spliceosome [37]. MicroRNA are short (~22 nucleotides) RNA sequences that bind to complementary sequences on target mRNA, thereby blocking translation or promoting degradation of target mRNA [37]. SnoRNA and miRNA are expressed in the brain and both classes of small RNAs have been implicated in neuroplasticity mechanisms and neurological disorders. For example, recent evidence suggests a role of the HBII52 small nucleolar RNA in the regulation of alternative splicing of the serotonin 2c receptor [38], and that patients with autism and Prader-Willi-like characteristics are found to have reduced levels of HBII52 in the brain [39]. The miRNA miR132 is induced by neuronal activity and neurotrophins in a CREB-dependent manner and plays a role in regulating neuronal morphology and cellular excitability [40]. Moreover, preclinical evidence in rodent models demonstrated that small RNA expression is affected in the brain by TBI. Redell et al. [8] reported transient elevated expression

Figure 3. Independent quantitative real-time polymerase chain reaction (qPCR) assays confirmed that 13 small RNA TBI biomarkers are differentially regulated in PBMCs of mTBI relative to non-mTBI control cases. PBMC contents for each of the 18 candidate small RNA biomarkers identified by the high-throughput Array Chip platform in Figure 2 were quantitatively assessed using independent qPCR assays. The same 9 mTBI and 9 non-mTBI cases (Table 1) we used in our initial high-throughput biomarker discovery assay were assessed in this qPCR biomarker confirmation study. Bar graphs represent mean small RNA biomarker contents in the mTBI group relative to the non-mTBI group; error bars represent standard errors. * False discovery rate-corrected P-value < 0.05. qPCR confirmed 13 small RNA biomarker species are significantly down-regulated in PBMC of mTBI compared to non-mTBI veteran cases. These 13 confirmed small RNA biomarkers include 12 small nucleolar RNA (ACA48, ENSG199411, HBII-239, HBII-289, U15B, U27, U35A, U55, U56, U58B, U83A, U91) and 1 miRNA (Has-miR-671-5p) species.
Biological surrogates for distinguishing TBI from PTSD

miRNA species in the rat cerebral cortex up to 72 hrs following fluid percussion injury to the brain. Redell et al [42] also identified potential up-regulation of 35 and down-regulation of 50 miRNA species in the hippocampus of rats within 72 hrs following an impact TBI to the brain; altered regulations for a smaller subset of 8 (4 up-regulated and 4 down-regulated) miRNA species in the hippocampus were subsequently confirmed by independent qPCR.

It is possible that the altered regulation of select small nuclear RNA and miRNA that we observed in PBMCs of veteran mTBI cases might have implications in the central nervous system. Genes relevant to neural circuits, synapses and neural plasticity processes are also expressed in circulating blood cells, such as PBMCs. Thus, the fact that we observed significant down-regulation of select small RNA biomarkers in PBMC specimens from our veteran mTBI cases long after their deployment might reflect long-term molecular alterations in the central nervous system contributing to the onset and progression of clinical TBI phenotypes. Future studies exploring the physiological relevance of mTBI biomarkers will provide a better understanding of the biological mechanisms underlying mTBI and insights into novel therapeutic targets for mTBI.

Acknowledgments

These studies are supported by a Department of Defense award (W81XWH-08-2-0026) to Giulio Maria Pasinetti and in part by the National Institutes of Health (grant AG029310).

Please address correspondence to: Dr. Giulio Maria Pasinetti, Department of NeurologyMount Sinai

Figure 4. The content of small RNA biomarkers in clinically accessible PBMCs provides a sensitive and specific criterion for dissecting mTBI from non-mTBI veteran cases. We tested the role of the 13 qPCR confirmed small RNA mTBI biomarkers as a criterion for distinguishing mTBI from non-mTBI cases. Biomarker contents in banked PBMC specimens from the same 9 mTBI and 9 non-mTBI cases (Table 1) were used in our biomarker discovery studies and quantified by qPCR. (A,B) The efficacy of using biomarker contents from clinically accessible PBMCs as a criterion to correctly segregate mTBI and non-mTBI cases was tested by unsupervised clustering analysis using the UPGMA algorithm with cosine correlation as the similarity metric. Results are presented as heat maps demonstrating the efficacy of using all 13 small RNA biomarkers (A) or using a panel of three small nucleolar RNA biomarkers (B) to correctly segregate mTBI from non-mTBI cases. (B) A three small nucleolar RNA biomarker panel (HBII-289, ENSG199411 and U35A) is capable of distinguishing mTBI from non-mTBI cases with 89% accuracy, 82% selectivity and 78% specificity (accuracy is the percentage of all mTBI and non-mTBI cases that are correctly identified; selectivity is the probability that a case identified as mTBI actually is a mTBI case; specificity is the probability that a case identified as a non-mTBI case is actually a non-mTBI case). Abbreviations: snoRNA, small nucleolar RNA; miRNA, microRNA.
References


[25] Donnelly KT, Donnelly JP, Dunnam M, Warner GC, Kittleson CJ, Constance JE, Bradshaw CB, and Alt M. Reliability, sensitivity, and specific-
Biological surrogates for distinguishing TBI from PTSD


